Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

makrodimutross Jun. 3 at 3:31 PM

$FBIOP Seeking Alpha moderators are not allowing my comment on their board. What a shame.

2 · Reply

makrodimutross Jun. 1 at 8:15 PM

$FBIOP Wrong. If FBIOP were paying dividends, hadn't yet squared the arrears, and the market dictated an 8% forward yield (similar to Care Cloud CCLDO Class B Stock, recently redeemed).... The Price would be 33.98 per share. Consisting of: +25.00 liq pref +4.69 arrears +(0.09375*25)/0.08 (8% forward yield adder of 4.30)

3 · Reply

makrodimutross Jun. 1 at 8:05 PM

$FBIO commons realizing they owe $FBIOP 16M cash and a continued forward yield between 8-11%

0 · Reply

ItsThrillhouse Jun. 1 at 2:31 PM

$FBIOP man, you'd think this was paying some dividends. 😅

0 · Reply

Alex1m2 Jun. 1 at 2:20 PM

$FBIOP Over 20$🎉 Someone wants to buy all available shares!

2 · Reply

ItsThrillhouse May. 29 at 10:23 PM

$FBIOP https://seekingalpha.com/article/4910163-fortress-biotech-is-it-time-to-pay-deferred-preferred-stock-dividends

1 · Reply

SuperGreenToday May. 29 at 12:19 AM

$FBIOP

1 · Reply

deembi May. 28 at 10:21 PM

$FBIOP $FBIO The preferred is on a tear since the Q1 numbers got published showing a huge negative EV…up 38% from the day prior - $14.02 to a $19.40 close.

1 · Reply

Chaka1647 May. 28 at 9:09 PM

$FBIOP board is nice and quiet as stock moves to its righful place! Much more active when the price didn't make sense!

0 · Reply

deembi May. 28 at 5:58 PM

$FBIOP I asked Perplexity to review the preferred stock’s prospectus and summarize whether the interest payments are taxed as ordinary income or qualified dividends. Here is the summary: “QuantumOnline’s prospectus summary for FBIOP says the security pays a fixed dividend and explicitly describes the issue as a “9.375% Series A Cumulative Redeemable Perpetual Preferred Shares” with dividends payable monthly. It also says the dividend is eligible for the preferential dividend tax rate, which is a strong sign the issuer and offering documents treat the payments as stock dividends rather than bond interest.” Anyone who received interest payments in the past, do you recall whether you received a 1099-DIV or a 1099-INT?

1 · Reply

Fortress Biotech Transcript: A.G.P.'s Annual Virtual Healthcare Conference

May 19, 2026, 4:45 PM EDT - 16 days ago

Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference

DERM

2026-05-18T13:00:31.000Z - 17 days ago

Fortress Biotech price target raised to $5 from $4.50 at Alliance Global

DERM

May 18, 2026, 8:30 AM EDT - 17 days ago

Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference

FBIOP

May 14, 2026, 4:10 PM EDT - 21 days ago

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

FBIOP

May 13, 2026, 4:01 PM EDT - 22 days ago

Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

DERM

May 13, 2026, 4:00 PM EDT - 22 days ago

Fortress Biotech Earnings Call Transcript: Q1 2026

May 13, 2026, 4:00 PM EDT - 22 days ago

Fortress Biotech Quarterly report: Q1 2026

May 13, 2026, 4:00 PM EDT - 22 days ago

Fortress Biotech Earnings release: Q1 2026

May 6, 2026, 4:01 PM EDT - 4 weeks ago

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

DERM

May 4, 2026, 8:30 AM EDT - 4 weeks ago

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

FBIOP

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Fortress Biotech Proxy statement: Proxy filing

Apr 27, 2026, 7:00 AM EDT - 5 weeks ago

Fortress Biotech Proxy statement: Proxy filing

Apr 22, 2026, 7:00 AM EDT - 6 weeks ago

Fortress Biotech Slides: Corporate presentation

Apr 21, 2026, 8:30 AM EDT - 6 weeks ago

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

DERM

Mar 31, 2026, 4:05 PM EDT - 2 months ago

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

FBIOP

Mar 31, 2026, 4:00 PM EDT - 2 months ago

Fortress Biotech Earnings release: Q4 2025

Mar 30, 2026, 4:05 PM EDT - 2 months ago

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Mar 25, 2026, 4:01 PM EDT - 2 months ago

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

DERM

Mar 19, 2026, 7:00 AM EDT - 2 months ago

Fortress Biotech Slides: Corporate presentation

Mar 18, 2026, 8:30 AM EDT - 2 months ago

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

DERM

Feb 23, 2026, 9:24 AM EST - 3 months ago

UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

FBIOP

2026-02-23T13:53:18.000Z - 3 months ago

Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

Feb 23, 2026, 8:30 AM EST - 3 months ago

Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

FBIOP

Feb 23, 2026, 8:00 AM EST - 3 months ago

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

2026-01-13T12:50:22.000Z - 5 months ago

Fortress Biotech, Cyprium announce FDA approval of ZYCUBO

Jan 13, 2026, 7:45 AM EST - 5 months ago

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

FBIOP

Dec 16, 2025, 7:00 AM EST - 6 months ago

Fortress Biotech Registration statement: Registration Filing

2025-12-16T11:11:34.000Z - 6 months ago

Fortress Biotech files to sell 600,000 shares of common stock for holders

2025-12-15T13:10:58.000Z - 6 months ago

Fortress Biotech, Cyprium announce FDA acceptance of CUTX-101 NDA resubmission

Dec 15, 2025, 8:00 AM EST - 6 months ago

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

Dec 10, 2025, 8:30 AM EST - 6 months ago

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

DERM

2025-11-19T12:15:57.000Z - 7 months ago

Fortress Biotech price target raised to $4.50 from $4 at Alliance Global

2025-11-14T13:40:48.000Z - 7 months ago

Fortress Biotech reports Q3 EPS 11c vs (76c) last year

Nov 14, 2025, 8:30 AM EST - 7 months ago

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Nov 12, 2025, 4:30 PM EST - 7 months ago

Fortress Biotech Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

Fortress Biotech Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

Fortress Biotech Earnings release: Q3 2025

Nov 12, 2025, 4:01 PM EST - 7 months ago

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Nov 6, 2025, 7:00 AM EST - 7 months ago

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

AXSM

Nov 5, 2025, 8:30 AM EST - 7 months ago

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

DERM

Oct 24, 2025, 8:30 AM EDT - 7 months ago

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

DERM

2025-10-21T12:35:27.000Z - 8 months ago

Fortress subsidiary announces Crystalys dosed patient in study of dotinurad

Oct 21, 2025, 8:30 AM EDT - 8 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout

FBIOP

Oct 8, 2025, 8:30 AM EDT - 8 months ago

Journey Medical Corporation to Participate in October 2025 Investor Conferences

DERM

Oct 1, 2025, 3:45 PM EDT - 8 months ago

Fortress Biotech Investigated by the Portnoy Law Firm

2025-10-01T13:07:24.000Z - 8 months ago

Why Is Fortress Biotech Stock (FBIO) Down 30% Today?

2025-10-01T12:30:16.000Z - 8 months ago

Fortress Biotech, Urica announces Crystalys’ $205M Series A financing

2025-10-01T12:11:28.000Z - 8 months ago

Fortress Biotech, Cyprium receive CRL related to NDA for CUTX-101

Oct 1, 2025, 8:05 AM EDT - 8 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

FBIOP

Oct 1, 2025, 8:00 AM EDT - 8 months ago

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

FBIOP

Sep 3, 2025, 8:30 AM EDT - 9 months ago

Journey Medical Corporation to Participate in September 2025 Investor Conferences

DERM

Sep 2, 2025, 8:30 AM EDT - 9 months ago

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FBIOP

2025-08-21T10:20:36.000Z - 10 months ago

Fortress Biotech price target lowered to $17 from $26 at H.C. Wainwright

2025-08-19T12:15:37.000Z - 10 months ago

Fortress Biotech price target lowered to $12 from $15 at Roth Capital

Aug 18, 2025, 8:30 AM EDT - 10 months ago

Journey Medical Corporation to Present at the Emerging Growth Conference

DERM

Aug 14, 2025, 4:05 PM EDT - 10 months ago

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Aug 12, 2025, 4:01 PM EDT - 10 months ago

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Aug 12, 2025, 4:00 PM EDT - 10 months ago

Fortress Biotech Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 10 months ago

Fortress Biotech Earnings release: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 10 months ago

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

DERM

Aug 5, 2025, 4:01 PM EDT - 10 months ago

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

DERM

Jul 14, 2025, 8:30 AM EDT - 11 months ago

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

DERM

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

DERM

Jun 20, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

DERM

Jun 17, 2025, 10:00 AM EDT - 1 year ago

Fortress Biotech Transcript: AGM 2025

Jun 9, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

DERM

May 30, 2025, 10:47 AM EDT - 1 year ago

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

FBIOP

May 15, 2025, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

May 15, 2025, 4:00 PM EDT - 1 year ago

Fortress Biotech Quarterly report: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

Fortress Biotech Earnings release: Q1 2025

May 14, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

May 13, 2025, 4:15 PM EDT - 1 year ago

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

CKPT

2025-05-08T15:45:41.000Z - 1 year ago

Fortress Biotech management to meet virtually with Roth MKM

May 7, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

DERM

May 7, 2025, 8:00 AM EDT - 1 year ago

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

FBIOP

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Fortress Biotech Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Fortress Biotech Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Fortress Biotech Proxy statement: Proxy Filing

Apr 1, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

DERM

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

CKPT

Mar 26, 2025, 4:30 PM EDT - 1 year ago

Fortress Biotech Earnings Call Transcript: Q4 2024

Mar 26, 2025, 4:30 PM EDT - 1 year ago

Fortress Biotech Annual report: Q4 2024

Mar 26, 2025, 4:30 PM EDT - 1 year ago

Fortress Biotech Earnings release: Q4 2024

Mar 26, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

DERM

2025-03-17T13:07:15.000Z - 1 year ago

Fortress Biotech, Partex enter collaboration for asset identification

2025-03-17T13:00:50.000Z - 1 year ago

Fortress Biotech, Partex enter collaboration for asset identification, evaluatio

makrodimutross Jun. 3 at 3:31 PM

$FBIOP Seeking Alpha moderators are not allowing my comment on their board. What a shame.

2 · Reply

makrodimutross Jun. 1 at 8:15 PM

3 · Reply

makrodimutross Jun. 1 at 8:05 PM

$FBIO commons realizing they owe $FBIOP 16M cash and a continued forward yield between 8-11%

0 · Reply

ItsThrillhouse Jun. 1 at 2:31 PM

$FBIOP man, you'd think this was paying some dividends. 😅

0 · Reply

Alex1m2 Jun. 1 at 2:20 PM

$FBIOP Over 20$🎉 Someone wants to buy all available shares!

2 · Reply

ItsThrillhouse May. 29 at 10:23 PM

$FBIOP https://seekingalpha.com/article/4910163-fortress-biotech-is-it-time-to-pay-deferred-preferred-stock-dividends

1 · Reply

SuperGreenToday May. 29 at 12:19 AM

$FBIOP

1 · Reply

deembi May. 28 at 10:21 PM

$FBIOP $FBIO The preferred is on a tear since the Q1 numbers got published showing a huge negative EV…up 38% from the day prior - $14.02 to a $19.40 close.

1 · Reply

Chaka1647 May. 28 at 9:09 PM

$FBIOP board is nice and quiet as stock moves to its righful place! Much more active when the price didn't make sense!

0 · Reply

deembi May. 28 at 5:58 PM

1 · Reply

makrodimutross May. 28 at 4:25 AM

$FBIOP $FBIO This is nice, but extremely conservative (not a bad thing). ZYCUBO milestone payments totaling 128m, to come within 3 years. CAEL-101 sounds like it will be approved this year, 19m on approval, and a further 106m in milestone payments... though Less likely to hit all milestones due to the forthcoming limited indication (subgroup). 2028 and 2029 will most likely have Dotinrad royalties. I do like that someone else here is thinking about the future DERM dividends to FBIO after the SWK loan is satisfied. Maybe FBIO buys DERM shares in a PP, and DERM uses the cash to pay out the remaining SWK loan? Interesting few years ahead, but very optimistic.

3 · Reply

1000kv May. 28 at 2:24 AM

$FBIOP Claude and I ran some cash flow scenarios, high level, thought I would share, but as always please do your own DD.

2 · Reply

makrodimutross May. 26 at 6:05 PM

$FBIOP $FBIO $CCLDO maybe someone important found this yield chart? What else will the company do with a 200m war chest?

2 · Reply

makrodimutross May. 26 at 3:57 PM

$FBIOP $FBIO https://www.prnewswire.com/news-releases/crystalys-therapeutics-doses-first-patients-in-new-phase-2-trial-of-dotinurad-for-difficult-to-treat-gout-302778670.html Onwards

0 · Reply

swift107 May. 26 at 2:53 PM

$FBIOP it’s happening!

0 · Reply

Alex1m2 May. 26 at 2:28 PM

$FBIOP Well well it looks like people that can do basic math have discovered this hidden Gem.

0 · Reply

Chaka1647 May. 26 at 12:11 PM

$FBIOP lot of premarket for some reason

1 · Reply

Sawnchey May. 24 at 1:25 PM

$FBIO $FBIOP I took the time to listen to Sun Pharma and Zydus's earnings calls for any colour on Unloxcyt and Zycubo launches. Neither really spoke about them too much. The only particular details came out of the Sun call and those were: 1. Physician feedback is in line with expectations for Unloxcyt safety & tolerability - with some repeat orders already. 2. They are not restricting Unloxcyt marketing to a specific set of centres or accounts, they are going for broad adoption. 3. Ex-US regulatory filings will not be happening anytime soon. They said the package for FDA does not fully translate to other regulators and so this will be a future consideration rather than near term. So nothing particularly exciting, but good to hear that the launches are progressing. For both companies this isn’t their first rodeo, so hopefully as the quarters move forwards we will see some growth in royalties to help ease the cash burn for the parent company and Cyprium.

2 · Reply

makrodimutross May. 22 at 6:19 AM

$FBIO $FBIOP what if they’re waiting for Triplex data to be published before deciding to reinstate dividends? ...bad data And dividend reinstatement may kneecap the common shares to below the 1 dollar minimum bid. They'd have 180 days to bring the minimum bid back. ...They might be waiting to see exactly what kind of effect bad P2 data for Triplex in the HIV indication would have on the common stock... it's obvious what Good Triplex data could do to both FBIO and FBIOP.

3 · Reply

1000kv May. 22 at 2:41 AM

$FBIOP Sun Reports tomorrow, should get an initial read on Unloxyte since the launch.

0 · Reply

makrodimutross May. 21 at 5:16 PM

$FBIOP $FBIO I made a yield value chart for your perusal. Holding size is based on Lindsay Rosenwald's disclosed position in FBIOP as of July 11th, 2024 (127,500 shares). The reason I chose the 8% forward yield figure is because Care Cloud's (recently redeemed class B) $CCLDO preferred stock was trading at this forward yield, and it was in a similar position as FBIOP is now. https://www.sec.gov/Archives/edgar/data/941841/000110465924079855/0001104659-24-079855-index.html The current month is highlighted in green to show the value of his holdings in the preferred stock only. If the BOD votes to make good on the arrears, he will receive $572,475 USD for the $4.49 per share owed. If this happens, I wonder if he will reinvest that cash into the company given that they believe they are no longer in need of any equity financing into the future?

4 · Reply

StockBodega May. 20 at 4:58 PM

$FBIO $FBIOP $DERM Nothing really surprising or interesting in the fireside chat LR just pretty much went through the slide presentation on their website and tried to better explain thaier business model but hopefully it will generate some stock purchase. He did say that they don't think they will need to borrow any more money and after paying down the loan their expenses should be down to about 10 million so thats good news. I think they earned 16 million last quarter aside from the PRV sale. He also said he thought DERM would be well on their way within the next 2 quarters ...DERM's chat is at 5:30 today.

2 · Reply

Market Cap	N/A
Revenue (ttm)	84.51M
Net Income (ttm)	-60.64M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	304
Avg Vol	18,892
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	79%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A